网红黑料

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical鈥�

Investigator

Torge Rempe

Status

Accepting Candidates

Ages

18 Years - 55 Years

Sexes

All

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early鈥�

Investigator

Torge Rempe

Status

Accepting Candidates

Ages

18 Years - 60 Years

Sexes

All